Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer.

ABSTRACT:

Background

Several studies have reported the efficacy of cabazitaxel in cancer therapy; however, investigations of its safety are few. The aim of this study was to retrospectively analyze the efficacy and safety of cabazitaxel based on treatment outcome data.

Methods

A questionnaire form on the use of cabazitaxel was mailed to hospitals associated with the Shinshu University. Responses were received from 11 institutions regarding 55 cases.

Results

Patients received a median of 4 courses of cabazitaxel treatment. Decreases in prostrate-specific antigen (PSA) were observed in 61.5% of cases with declines of 30%, 50%, and 90% in 36.5%, 23.0%, and 7.6% of cases, respectively. PSA progression-free survival was 5.0 months, and overall survival after the start of cabazitaxel

SUBMITTER: Yamamoto T 

PROVIDER: S-EPMC7125373 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature